Contrast-induced nephropathy.

Radiological procedures utilizing intravascular iodinated contrast media are being widely applied for both diagnostic and therapeutic purposes and represent one of the main causes of contrast-induced nephropathy (CIN) and hospital-acquired renal failure. Due to the lack of any effective treatment, prevention of this iatrogenic disease, which is associated with significant in-hospital and long-term morbidity and mortality and increased costs, is the key strategy. However, prevention of CIN continues to elude clinicians and is a major concern during percutaneous coronary interventions (PCI), as patients undergoing these procedures often have multiple comorbidities. The purpose of this article is to examine the pathophysiology, risk factors, and clinical course of CIN, as well as the most recent studies dealing with its prevention and potential therapeutic interventions, especially during PCI.

[1]  M. Rudnick,et al.  Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. , 2000, Kidney international.

[2]  R. Gupta,et al.  The renal patient with coronary artery disease: current concepts and dilemmas. , 2004, Journal of the American College of Cardiology.

[3]  N. Chalmers,et al.  Comparison of iodixanol and iohexol in renal impairment. , 1999, The British journal of radiology.

[4]  G. Stone,et al.  A risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention , 2003 .

[5]  P. Aspelin,et al.  Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach , 2006, Circulation.

[6]  M. Leon,et al.  Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. , 1999, The American journal of cardiology.

[7]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[8]  F. Veglia,et al.  Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[9]  M. Tonelli,et al.  Systematic review of the impact of N-acetylcysteine on contrast nephropathy. , 2004, Kidney international.

[10]  W. O’Neill,et al.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.

[11]  A. Wragg,et al.  A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. , 2003, Journal of the American College of Cardiology.

[12]  Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. , 2002 .

[13]  M. Rich,et al.  Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. , 1990, Archives of internal medicine.

[14]  Sven-Göran Fransson,et al.  Nephrotoxic effects in high-risk patients undergoing angiography. , 2003, The New England journal of medicine.

[15]  S. Hou,et al.  Hospital-acquired renal insufficiency. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  B. Krämer,et al.  The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. , 2004, Journal of the American Society of Nephrology : JASN.

[17]  F. Markowetz,et al.  Acetylcysteine for prevention of contrast nephropathy: meta-analysis , 2003, The Lancet.

[18]  K. Shojania,et al.  Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. , 2004, The American journal of medicine.

[19]  D. Malenka,et al.  N‐acetylcysteine prophylaxis significantly reduces the risk of radiocontrast‐induced nephropathy: Comprehensive meta‐analysis , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  Samin K. Sharma,et al.  Cardiac Angiography in Renally Impaired Patients (CARE) Study: A Randomized Double-Blind Trial of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease , 2007, Circulation.

[21]  Allen J. Taylor,et al.  Clinical InvestigationsCardiologyPREPARED: PREParation for Angiography in REnal Dysfunction: A Randomized Trial of Inpatient vs Outpatient Hydration Protocols for Cardiac Catheterization in Mild-to-Moderate Renal Dysfunction , 1998 .

[22]  L. Gruberg Clinical features and prognostic implications of contrast-induced nephropathy , 2005 .

[23]  G. Dangas,et al.  Acute renal failure requiring dialysis after percutaneous coronary interventions , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[24]  J. Ix,et al.  N-acetylcysteine for the prevention of contrast-induced nephropathy , 2005, Journal of General Internal Medicine.

[25]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.

[26]  Douglas Losordo,et al.  Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). , 2002, The American journal of cardiology.

[27]  P. Persson,et al.  Contrast medium-induced nephropathy: the pathophysiology. , 2006, Kidney international. Supplement.

[28]  G. Marenzi,et al.  The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. , 2003, The New England journal of medicine.

[29]  K. Harjai,et al.  Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. , 2004, The American journal of cardiology.

[30]  F. Veglia,et al.  N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty , 2006 .

[31]  R. Bersin,et al.  Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. , 2004, JAMA.

[32]  R. Erbel,et al.  Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. , 2006, Clinical nephrology.

[33]  S. Sdringola,et al.  Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[34]  J. Bover,et al.  Does hydration prevent radiocontrast-induced acute renal failure? , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  Kirk N. Garratt,et al.  Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention , 2002, Circulation.

[36]  F. Veglia,et al.  Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. , 2006, The American journal of medicine.

[37]  F. Veglia,et al.  Contrast Volume During Primary Percutaneous Coronary Intervention and Subsequent Contrast-Induced Nephropathy and Mortality , 2009, Annals of Internal Medicine.

[38]  Gilles Soulez,et al.  Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Computed Tomography: A Double-Blind Comparison of Iodixanol and Iopamidol , 2006, Investigative radiology.

[39]  C. Briguori,et al.  Contrast-induced nephropathy: pharmacological prophylaxis. , 2006, Kidney international. Supplement.

[40]  E. Kline-Rogers,et al.  Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. , 2005, The American journal of medicine.

[41]  W. O’Neill,et al.  A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy ☆: Results of the P.R.I.N.C.E. study , 1999 .

[42]  E. Bates,et al.  Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  A. Szabo,et al.  High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. , 2009, The American journal of medicine.

[44]  A. Agrawal,et al.  A Randomized Prospective Trial to Assess the Role of Saline Hydration on the Development of Contrast Nephrotoxicity , 2003, Nephron Clinical Practice.

[45]  E. Halpern,et al.  Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. , 1995, Kidney international.

[46]  D. Cokkinos,et al.  Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study , 2006, European Journal of Clinical Pharmacology.

[47]  H. Miller,et al.  Effects of an Acute Dose of L-Arginine during Coronary Angiography in Patients with Chronic Renal Failure , 2003, American Journal of Nephrology.

[48]  P. Nilsson-ehle,et al.  Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. , 1995, Nephron.

[49]  G. Sterner,et al.  Does Post-angiographic Hemodialysis Reduce the Risk of Contrast-medium Nephropathy? , 2000, Scandinavian journal of urology and nephrology.

[50]  R. Luther,et al.  The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. , 1999, Critical care medicine.

[51]  T. Lehnert,et al.  Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  G. Deray,et al.  How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. , 2006, Kidney international. Supplement.

[53]  R. Gupta,et al.  Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. , 1999, Indian heart journal.

[54]  J. Yee,et al.  The potential role of statins in contrast nephropathy. , 2004, Clinical nephrology.

[55]  A. Serra,et al.  Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. , 2001, The American journal of medicine.

[56]  G. Marenzi,et al.  Recent advances in the prevention of radiocontrast-induced nephropathy , 2004, Current opinion in critical care.

[57]  B. Jaber,et al.  Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[58]  J. Kaski,et al.  The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. , 2007, Journal of the American College of Cardiology.

[59]  C. Poole,et al.  N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. , 2004, Journal of the American Society of Nephrology : JASN.

[60]  Young‐Bae Park,et al.  Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. , 2006, Journal of the American College of Cardiology.

[61]  J. D'Elia,et al.  Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. , 1994, The New England journal of medicine.

[62]  M. Gotsman,et al.  The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. , 1999, Journal of the American College of Cardiology.

[63]  S. Bagshaw,et al.  Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis , 2004, BMC medicine.

[64]  Chi‐Hang Lee,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.

[65]  M. Shapiro,et al.  Role of N‐acetylcysteine in prevention of contrast‐induced nephropathy after cardiovascular procedures: A meta‐analysis , 2004, Clinical cardiology.

[66]  R. Bellomo,et al.  Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients* , 2007, Critical care medicine.

[67]  R. Katzberg,et al.  Contrast-induced nephrotoxicity: clinical landscape. , 2006, Kidney international. Supplement.

[68]  A. Wenning,et al.  Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[69]  B. Barrett,et al.  Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. , 1993, Radiology.

[70]  R. Katzberg,et al.  Risk of iodinated contrast material--induced nephropathy with intravenous administration. , 2007, Radiology.

[71]  K. Shyu,et al.  Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. , 2002, Journal of the American College of Cardiology.

[72]  T. L. Pinto,et al.  Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. , 2006, The American journal of cardiology.

[73]  D. Greenwood,et al.  Ascorbic Acid Prevents Contrast-Mediated Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention , 2004, Circulation.

[74]  Aslihan Büyüköztürk Karul,et al.  Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures , 2006, Heart.

[75]  P. Persson,et al.  Pathophysiology of contrast medium-induced nephropathy. , 2005, Kidney international.

[76]  G. Stone,et al.  Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. , 2003, JAMA.

[77]  D. Roe,et al.  Predicting angiography-induced acute renal function impairment: clinical risk model. , 1983, AJR. American journal of roentgenology.

[78]  V. Guru,et al.  The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. , 2004, Clinical nephrology.

[79]  P. Parfrey,et al.  Preventing Nephropathy Induced by Contrast Medium , 2006 .

[80]  Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies , 2007 .

[81]  C. Viscoli,et al.  The effect of acute renal failure on mortality. A cohort analysis. , 1996, JAMA.

[82]  A. Colombo,et al.  Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. , 2004, European heart journal.

[83]  C. McCulloch,et al.  Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[84]  Jiaquan Zhu,et al.  N-acetylcysteine to ameliorate acute renal injury in a rat cardiopulmonary bypass model. , 2007, The Journal of thoracic and cardiovascular surgery.

[85]  B. Villari,et al.  Acetylcysteine and contrast agent-associated nephrotoxicity. , 2002, Journal of the American College of Cardiology.